Xeris Biopharma Holdings
XERS
120 hedge funds and large institutions have $144M invested in Xeris Biopharma Holdings in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 31 reducing their positions, and 12 closing their positions.
926% more call options, than puts
Call options by funds: $1.95M | Put options by funds: $190K
83% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 12
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
40% more capital invested
Capital invested by funds: $102M → $144M (+$41.4M)
19% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 31
9% more funds holding
Funds holding: 110 → 120 (+10)
4.42% more ownership
Funds ownership: 39.85% → 44.27% (+4.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.33M |
| 2 |
BlackRock
New York
|
+$1.18M |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$1.05M |
| 4 |
DMKJ
David M. Knott Jr
|
+$716K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$685K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.34M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.22M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$725K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$531K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$473K |
XERS Hedge Fund Activity: Q4 2023 in Review
120 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q4 2023, worth a combined $144M — up 40% from $102M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new XERS positions and 12 closed out — a net gain of 10 holders — while 37 added to existing stakes and 31 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.33M. The largest seller was Millennium Management, cutting an estimated $1.34M.
- 120 institutional investors held Xeris Biopharma Holdings (XERS) as of Q4 2023, up from 110 in Q3 2023.
- Funds reported $144M of Xeris Biopharma Holdings stock for Q4 2023, up 40% quarter-over-quarter.
- 22 funds opened new Xeris Biopharma Holdings positions in Q4 2023 and 12 closed out, a net change of +10 holders.
- The largest Xeris Biopharma Holdings buyer in Q4 2023 was Morgan Stanley, an estimated $3.33M added.
- The largest Xeris Biopharma Holdings seller in Q4 2023 was Millennium Management, an estimated $1.34M sold.
Based on aggregated 13F filings for Q4 2023.